Ortin Laboratories Reports Negative Financial Results for Q4 2023

Ortin Laboratories, a microcap pharmaceutical company, recently announced its financial results for the quarter ending December 2023. The company's performance has been deemed negative, with a score of -9 compared to -3 in the previous quarter.

The profit before tax (PBT) less other income for the quarter was at a low of -2.81 crore, showing a significant decline of 724.44% year on year. This trend is expected to continue in the near term. Similarly, the profit after tax (PAT) for the quarter was at -2.79 crore, a decrease of 706.5% year on year. The operating profit (PBDIT) for the quarter was also at its lowest in the last five quarters, at -2.60 crore. This indicates a negative trend in the company's operating profit.

The company's earnings per share (EPS) for the quarter were at a low of -3.43, showing a decline in profitability and lower earnings for shareholders. Based on these financials, MarketsMOJO has given a 'Strong Sell' call for Ortin Labs.

It is important to note that these financial results are based on the company's performance in the past quarter and do not reflect any potential for future growth. As a microcap company, Ortin Laboratories may face challenges in the highly competitive pharmaceutical industry. Investors are advised to carefully consider all factors before making any investment decisions.